Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: A population-based study

European Journal of Endocrinology

Volumn 171, Issue 2, 2014, Pages 199-207

  Ramezani Tehrani, Fahimeh ^a   Minooee, Sonia ^a   Azizi, Fereidoun ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HOMEOSTASIS MODEL ASSESSMENT INDEX; HUMAN; INSULIN RESISTANCE; IRAN; IRANIAN PEOPLE; LIPID ACCUMULATION PRODUCT INDEX; MAJOR CLINICAL STUDY; MEASUREMENT; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; POPULATION RESEARCH; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; VISCERAL ADIPOSITY INDEX; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADIPOSITY; ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; IRAN; LIPIDS; METABOLIC SYNDROME X; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; WAIST CIRCUMFERENCE; WAIST-HIP RATIO;

EID: 84905262219     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0094     Document Type: Article

References (56)

1. Dunaif A, Graf M, Mandeli J, Laumas V & Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 1987 65 499-507. (doi:10.1210/jcem-65-3-499)
2. Conway GS, Agrawal R, Betteridge DJ & Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clinical Endocrinology 1992 37 119-125. (doi:10.1111/j.1365-2265.1992. tb02295.x)
3. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E & Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism 2010 95 2038-2049. (doi:10.1210/jc.2009-2724)
4. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 2006 30 13-17. (doi:10.1385/ENDO:30:1:13)
5. Duleba AJ. Medical management of metabolic dysfunction in PCOS. Steroids 2012 77 306-311. (doi:10.1016/j.steroids.2011.11.014)
6. Cussons AJ, Stuckey BG & Watts GF. Metabolic syndrome and cardiometabolic risk in PCOS. Current Diabetes Reports 2007 7 66-73. (doi:10.1007/s11892-007-0012-8)
7. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R & Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2013 98 4565-4592. (doi:10.1210/jc.2013-2350)
8. Godinjak A, Godinjak Z, Burekovic A, Surkovic I, Dizdarevic-Bostandzic A & Velija-Asimi Z. Insulin resistance and lipid accumulation product in corelation to body mass index in women with polycystic ovary syndrome. Medicinski Arhiv 2012 66 409-411. (doi:10.5455/medarh.2012.66.409-411)
9. Amato MC, Guarnotta V, Forti D, Donatelli M, Dolcimascolo S & Giordano C. Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment. Human Reproduction 2013 28 1919-1928. (doi:10.1093/humrep/det105)
10. Hosseinpanah F, Barzin M, Erfani H, Serahati S, Ramezani Tehrani F & Azizi F. Lipid accumulation product and insulin resistance in Iranian PCOS prevalence study. Clinical Endocrinology 2014. In press. (doi:10.1111/cen.12287)
11. Bener A, Yousafzai MT, Darwish S, Al-Hamaq AO, Nasralla EA & Abdul-Ghani M. Obesity index that better predictmetabolic syndrome: body mass index, waist circumference, waist hip ratio, or waist height ratio. Journal of Obesity 2013 2013 269038. (doi:10.1155/2013/269038)
12. Savva SC, Lamnisos D & Kafatos AG. Predicting cardiometabolic risk: waist-to-height ratio or BMI. A meta-analysis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013 6 403-419. (doi:10.2147/DMSO.S34220)
13. Zimmet P, Magliano D, Matsuzawa Y, Alberti G & Shaw J. The metabolic syndrome: a global public health problemand a new definition. Journal of Atherosclerosis and Thrombosis 2005 12 295-300. (doi:10.5551/jat.12.295)
14. Dobbelsteyn CJ, Joffres MR, MacLean DR & Flowerdew G. A comparative evaluation of waist circumference, waist-to-hip ratio and body mass index as indicators of cardiovascular risk factors. The Canadian Heart Health Surveys. International Journal of Obesity and Related Metabolic Disorders 2001 25 652-661. (doi:10.1038/sj.ijo.0801582)
15. Janssen I, Katzmarzyk PT & Ross R. Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Archives of Internal Medicine 2002 162 2074-2079. (doi:10.1001/archinte.162.18.2074)
16. Kahn HS. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovascular Disorders 2005 5 26. (doi:10.1186/1471-2261-5-26)
17. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M & Galluzzo A. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010 33 920-922. (doi:10.2337/dc09-1825)
18. Hosseinpanah F, Barzin M, Tehrani FR & Azizi F. The lack of association between polycystic ovary syndrome and metabolic syndrome: Iranian PCOS prevalence study. Clinical Endocrinology 2011 75 692-697. (doi:10.1111/j.1365-2265.2011.04113.x)
19. Essah PA & Nestler JE. The metabolic syndrome in polycystic ovary syndrome. Journal of Endocrinological Investigation 2006 29 270-280. (doi:10.1007/BF03345554)
20. Wiltgen D, Benedetto IG, Mastella LS & Spritzer PM. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Human Reproduction 2009 24 1726-1731. (doi:10.1093/humrep/dep072)
21. Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F & Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reproductive Biology and Endocrinology 2011 9 39. (doi:10.1186/1477-7827-9-39)
22. Rashidi H, Ramezani Tehrani F, Bahri Khomami M, Tohidi M & Azizi F. To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2013 174 100-105. (doi:10.1016/j.ejogrb.2013.12.018)
23. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004 19 41-47. (doi:10.1093/humrep/deh098)
24. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM & Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009 120 1640-1645. (doi:10.1161/CIRCULATIONAHA.109.192644)
25. Delavari A, Forouzanfar MH, Alikhani S, Sharifian A & Kelishadi R. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care 2009 32 1092-1097. (doi:10.2337/dc08-1800)
26. Tehrani FR, Rashidi H & Azizi F. The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study. Reproductive Biology and Endocrinology 2011 9 144. (doi:10.1186/1477-7827-9-144)
27. Wallace TM, Levy JC & Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004 27 1487-1495. (doi:10.2337/diacare.27.6.1487)
28. Zadeh-Vakili A, Tehrani FR & Hosseinpanah F. Waist circumference and insulin resistance: a community based cross sectional study on reproductive aged Iranian women. Diabetology & Metabolic Syndrome 2011 3 18. (doi:10.1186/1758-5996-3-18)
29. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatrica 2007 96 644-647. (doi:10.1111/j.1651- 2227.2006.00178.x)
30. Youden WJ. Index for rating diagnostic tests. Cancer 1950 3 32-35. (doi:10.1002/1097-0142(1950)3:132::AID-CNCR28200)
31. Flegal KM, Carroll MD, Ogden CL & Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. Journal of the American Medical Association 2010 303 235-241. (doi:10.1001/jama.2009.2014)
32. Lim SS, Davies MJ, Norman RJ & Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2012 18 618-637. (doi:10.1093/humupd/ dms030)
33. Svendsen PF, Nilas L, Norgaard K, Jensen JE & Madsbad S. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. Human Reproduction 2008 23 2113-2121. (doi:10.1093/humrep/den211)
34. Cosar E, Ucok K, Akgun L, Koken G, Sahin FK, Arioz DT & Bas O. Body fat composition and distribution in women with polycystic ovary syndrome. Gynecological Endocrinology 2008 24 428-432. (doi:10.1080/09513590802234253)
35. Godoy-Matos AF, Vaisman F, Pedrosa AP, Farias ML, Mendonca LM & Pinheiro MF. Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome. Gynecological Endocrinology 2009 25 793-798. (doi:10.3109/09513590903015528)
36. Karabulut A, Yaylali GF, Demirlenk S, Sevket O & Acun A. Evaluation of body fat distribution in PCOS and its association with carotid atherosclerosis and insulin resistance. Gynecological Endocrinology 2012 28 111-114. (doi:10.3109/09513590.2011.589929)
37. Yucel A, Noyan V & Sagsoz N. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2006 126 81-86. (doi:10.1016/j.ejogrb.2005.11.012)
38. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F, Di Fede G & Rini G. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. Journal of Clinical Endocrinology and Metabolism 2007 92 2500-2505. (doi:10.1210/jc.2006-2725)
39. Lee H, Oh JY, Sung YA & Chung H. Is insulin resistance an intrinsic defect in Asian polycystic ovary syndrome? Yonsei Medical Journal 2013 54 609-614. (doi:10.3349/ymj.2013.54.3.609)
40. Ketel IJ, Serne EH, Ijzerman RG, Korsen TJ, Twisk JW, Hompes PG, Smulders YM, Homburg R, Vorstermans L, Stehouwer CD et al. Insulin-induced capillary recruitment is impaired in both lean and obese women with PCOS. Human Reproduction 2011 26 3130-3137. (doi:10.1093/humrep/der296)
41. Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka G, Hill M, Fanta M, Vondra K & Skrha J. Insulin sensitivity in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2004 89 2942-2945. (doi:10.1210/jc.2003-031378)
42. Glueck CJ, Dharashivkar S, Wang P, Zhu B, Gartside PS, Tracy T & Sieve L. Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2005 122 206-212. (doi:10.1016/j.ejogrb.2005.03.010)
43. Hahn S, Tan S, Sack S, Kimmig R, Quadbeck B, Mann K & Janssen OE. Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome. Experimental and Clinical Endocrinology & Diabetes 2007 115 130-135. (doi:10.1055/s-2007-967093)
44. Vrbikova J, Dvorakova K, Grimmichova T, Hill M, Stanicka S, Cibula D, Bendlova B, Starka L & Vondra K. Prevalence of insulin resistance and prediction of glucose intolerance and type 2 diabetes mellitus in women with polycystic ovary syndrome. Clinical Chemistry and Laboratory Medicine 2007 45 639-644. (doi:10.1515/CCLM.2007.113)
45. Mukherjee S, Shaikh N, Khavale S, Shinde G, Meherji P, Shah N & Maitra A. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome. European Journal of Endocrinology 2009 160 855-862. (doi:10.1530/EJE-08-0932)
46. Wang K, Wang L, Zhao Y, Shi Y, Wang L & Chen ZJ. No association of the Arg51Gln and Leu72Met polymorphisms of the ghrelin gene and polycystic ovary syndrome. Human Reproduction 2009 24 485-490. (doi:10.1093/humrep/den430)
47. Panidis D, Tziomalos K, Chatzis P, Papadakis E, Delkos D, Tsourdi EA, Kandaraki EA & Katsikis I. Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome. European Journal of Endocrinology 2013 168 145-152. (doi:10.1530/EJE-12-0655)
48. Goodarzi MO, Dumesic DA, Chazenbalk G & Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Reviews. Endocrinology 2011 7 219-231. (doi:10.1038/nrendo.2010.217)
49. DeUgarte CM, Bartolucci AA & Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertility and Sterility 2005 83 1454-1460. (doi:10.1016/j. fertnstert.2004.11.070)
50. Mukherjee S & Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian Journal of Medical Research 2010 131 743-760.
51. Diamanti-Kandarakis E & Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews 2012 33 981-1030. (doi:10.1210/er.2011-1034)
52. Amato MC, Verghi M, Galluzzo A & Giordano C. The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Human Reproduction 2011 26 1486-1494. (doi:10.1093/humrep/der088)
53. Knowles KM, Paiva LL, Sanchez SE, Revilla L, Lopez T, Yasuda MB, Yanez ND, Gelaye B & Williams MA. Waist circumference, body mass index, and other measures of adiposity in predicting cardiovascular disease risk factors among peruvian adults. International Journal of Hypertension 2011 2011 931402. (doi:10.4061/2011/931402)
54. Wildman RP, Gu D, Reynolds K, Duan X, Wu X & He J. Are waist circumference and body mass index independently associated with cardiovascular disease risk in Chinese adults? American Journal of Clinical Nutrition 2005 82 1195-1202. (Pubitemid 43779717)
55. Vazquez G, Duval S, Jacobs DR Jr & Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiologic Reviews 2007 29 115-128. (doi:10.1093/epirev/mxm008)
56. Costa EC, Sa JC, Soares EM, Lemos TM, Maranhao TM & Azevedo GD. Anthropometric indices of central obesity how discriminators of metabolic syndrome in Brazilian women with polycystic ovary syndrome. Gynecological Endocrinology 2012 28 12-15. (doi:10.3109/09513590.2011.583956)